{"doi":"10.1128/aac.44.2.447-449.2000","title":"In Vitro Activity of ABT-773, a New Ketolide, against Recent Clinical Isolates of\n            <i>Streptococcus pneumoniae</i>\n            ,\n            <i>Haemophilus influenzae</i>\n            , and\n            <i>Moraxella catarrhalis</i>","abstract":"<jats:title>ABSTRACT</jats:title>\n          <jats:p>\n            The in vitro activity of ABT-773 was evaluated against\n            <jats:italic>Streptococcus pneumoniae</jats:italic>\n            ,\n            <jats:italic>Haemophilus influenzae</jats:italic>\n            , and\n            <jats:italic>Moraxella catarrhalis</jats:italic>\n            isolates. ABT-773 was the most active antimicrobial tested against\n            <jats:italic>S. pneumoniae</jats:italic>\n            . ABT-773 and azithromycin were equivalent in activity against\n            <jats:italic>H. influenzae</jats:italic>\n            and\n            <jats:italic>M. catarrhalis</jats:italic>\n            and more active than either clarithromycin or erythromycin.\n          </jats:p>","journal":"Antimicrobial Agents and Chemotherapy","year":2000,"id":679391,"datarank":0.5837730447165941,"base_score":3.8918202981106265,"endowment":3.8918202981106265,"self_citation_contribution":0.5837730447165941,"citation_network_contribution":0.0,"self_endowment_contribution":0.5837730447165941,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":48,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":145041,"name":"Gary V. Doern","orcid":null,"position":1,"is_corresponding":false},{"id":1775066,"name":"Holly K. Huynh","orcid":null,"position":2,"is_corresponding":false},{"id":1775068,"name":"Elizabeth M. Wingert","orcid":null,"position":3,"is_corresponding":false},{"id":716656,"name":"Paul R. Rhomberg","orcid":"0000-0001-6798-7653","position":4,"is_corresponding":false},{"id":1403899,"name":"Angela B. Brueggemann","orcid":"0000-0002-2329-1934","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"In Vitro Activity of ABT-773, a New Ketolide, against Recent Clinical Isolates of\n            <i>Streptococcus pneumoniae</i>\n            ,\n            <i>Haemophilus influenzae</i>\n            , and\n            <i>Moraxella catarrhalis</i>","abstract":"<jats:title>ABSTRACT</jats:title>\n          <jats:p>\n            The in vitro activity of ABT-773 was evaluated against\n            <jats:italic>Streptococcus pneumoniae</jats:italic>\n            ,\n            <jats:italic>Haemophilus influenzae</jats:italic>\n            , and\n            <jats:italic>Moraxella catarrhalis</jats:italic>\n            isolates. ABT-773 was the most active antimicrobial tested against\n            <jats:italic>S. pneumoniae</jats:italic>\n            . ABT-773 and azithromycin were equivalent in activity against\n            <jats:italic>H. influenzae</jats:italic>\n            and\n            <jats:italic>M. catarrhalis</jats:italic>\n            and more active than either clarithromycin or erythromycin.\n          </jats:p>","is_dataset_classified":null,"base_score":3.8918202981106265,"endowment":3.8918202981106265,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"10639382","pmcid":"PMC89703","openalex_id":"https://openalex.org/W2114205969","authors":[],"funders":[],"total_grants":0,"fwci":9.5264,"citation_percentile":0.98540166,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2013,"count":1},{"year":2016,"count":1},{"year":2017,"count":1},{"year":2019,"count":1}],"oa_status":"green","license":"https://journals.asm.org/non-commercial-tdm-license","oa_locations":[{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/89703","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/89703","host_type":"repository"},{"url":"https://journals.asm.org/doi/pdf/10.1128/AAC.44.2.447-449.2000","host_type":"publisher"},{"url":"https://doi.org/10.1128/aac.44.2.447-449.2000","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/10639382","host_type":"repository"}],"fields_of_study":["Pneumonia and Respiratory Infections","Pneumocystis jirovecii pneumonia detection and treatment","Chemical Synthesis and Analysis"],"mesh_terms":["Anti-Bacterial Agents","Moraxella catarrhalis","Erythromycin","Haemophilus influenzae","Humans","Microbial Sensitivity Tests","Streptococcus pneumoniae","Ketolides"],"keywords":["Moraxella catarrhalis","Haemophilus influenzae","Streptococcus pneumoniae","Moraxella (Branhamella) catarrhalis","Microbiology","Ketolide","Moraxella","Erythromycin","Antibacterial agent","Antimicrobial","Azithromycin","Biology","Antibiotics","Bacteria"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-17T13:04:59.771533Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}